<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503997</url>
  </required_header>
  <id_info>
    <org_study_id>VICC HN 0582</org_study_id>
    <secondary_id>VU-VICC-HN-0582</secondary_id>
    <secondary_id>VU-VICC-IRB-060100</secondary_id>
    <nct_id>NCT00503997</nct_id>
  </id_info>
  <brief_title>Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>Phase II Trial: Efficacy and Toxicity of Induction Pemetrexed (ALIMTA) and Oxaliplatin (ELOXATIN) in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving pemetrexed together with oxaliplatin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving pemetrexed together with oxaliplatin&#xD;
      works in treating patients with locally advanced head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the clinical response rate in patients with locally advanced squamous cell&#xD;
           carcinoma of the head and neck treated with neoadjuvant pemetrexed disodium and&#xD;
           oxaliplatin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the pathological complete response in patients who undergo surgical&#xD;
           resection or post-induction biopsy.&#xD;
&#xD;
        -  To assess toxicity of therapy, including the assessment of quality of life, fatigue, and&#xD;
           head and neck cancer-related symptoms.&#xD;
&#xD;
        -  To predict response and toxicities based on pharmacogenomics, genomics, and proteomics.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label study. Patients are assigned to 1 of 2 groups&#xD;
      based on resectability of disease (resectable vs nonresectable).&#xD;
&#xD;
        -  Group I (resectable disease): Patients receive pemetrexed disodium IV and oxaliplatin IV&#xD;
           over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient&#xD;
           progresses before receiving 4 courses of treatment, treatment will be discontinued and&#xD;
           patient will proceed to surgery.&#xD;
&#xD;
      After completion of pemetrexed disodium and oxaliplatin, patients undergo surgical resection&#xD;
      of disease.&#xD;
&#xD;
        -  Group II (nonresectable disease): Patients receive treatment as in group I. If patient&#xD;
           progresses before receiving 4 courses of treatment, treatment will be discontinued and&#xD;
           patient will proceed to concurrent chemoradiotherapy.&#xD;
&#xD;
      After completion of pemetrexed disodium and oxaliplatin, patients undergo concurrent&#xD;
      chemoradiotherapy.&#xD;
&#xD;
      Blood samples are collected at baseline and periodically during study for biomarker and&#xD;
      pharmacokinetic studies.&#xD;
&#xD;
      Quality of life is assessed prior to each course of therapy and at 4-6 weeks after the last&#xD;
      course.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Response to Treatment Measured by RECIST Criteria</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>RECIST response categories: Progressive disease (PD): &gt;=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): &gt;=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>drug therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.&#xD;
Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.</description>
    <arm_group_label>drug therapy</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <description>Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.&#xD;
Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.</description>
    <arm_group_label>drug therapy</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        Patients must meet all of the following criteria in order to be eligible for entry into the&#xD;
        trial:&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage III - IVB HNSCC (includes unknown&#xD;
             primary and ParaNasal Sinus cancers)but excludes nasopharyngeal, salivary gland or&#xD;
             skin primaries (No TNM staging required)&#xD;
&#xD;
          -  Patients must have a measurable disease defined by RECIST criteria&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  ECOG Performance Score of 0, 1 or 2&#xD;
&#xD;
          -  Adequate bone marrow as evidenced by:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1,500/μL&#xD;
&#xD;
               -  Platelet count &gt; 100,000/μL&#xD;
&#xD;
          -  Adequate renal function as evidenced by serum creatinine &lt; 1.5 mg/dL and CrCl &gt; 45&#xD;
             mL/min as determined by calculated creatinine clearance using the Cockroft-Gault&#xD;
             formula:&#xD;
&#xD;
               -  CrCl = (140-age) x (weight in kg)/72 x serum creatinine&#xD;
&#xD;
               -  Multiply by 0.85 (85%) for females&#xD;
&#xD;
          -  Adequate hepatic function as evidenced by:&#xD;
&#xD;
               -  Serum total bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 3X the ULN for the reference lab&#xD;
&#xD;
               -  SGOT/SGPT &lt; 3X the ULN for the reference lab&#xD;
&#xD;
          -  Patients or their legal representatives must be able to read, understand and provide&#xD;
             informed consent to participate in the trial.&#xD;
&#xD;
          -  Patients of childbearing potential and their partners must agree to use an effective&#xD;
             form of contraception during the study and for 90 days following the last dose of&#xD;
             study medication (an effective form of contraception is an oral contraceptive, double&#xD;
             barrier method or surgical intervention resulting in sterility).&#xD;
&#xD;
          -  Patients must be able to interupt NSAIDs at 2 days before (5 days for long-acting&#xD;
             NSAIDs),the day of, and 2 days following administration of Pemetrexed.&#xD;
&#xD;
          -  Patients must be willing and able to take Folic Acid (350-1000 μg) daily beginning 1&#xD;
             week (7 days) prior to the first dose of Pemetrexed and continued daily until 3 weeks&#xD;
             after the last dose of study therapy. In addition, patients must be willing to&#xD;
             maintain a Pill Diary as part of study compliance.&#xD;
&#xD;
          -  Patients must be willing and able to take Vitamin B12 (1000 μg) administered&#xD;
             intramuscularly beginning 1 week (7 days) prior to the first dose of Pemetrexed and&#xD;
             repeated at the planned End of Treatment visit (no later than 9 weeks from the first&#xD;
             injection).&#xD;
&#xD;
          -  Patients must be willing and able to take Dexamethasone (4 mg of oral or equivalent)&#xD;
             that should be given twice daily on the day before, the day of, and the day after each&#xD;
             dose of Pemetrexed for rash prophylaxis unless medically contraindicated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A patient may not be enrolled in the trial if any of the following criteria are met:&#xD;
&#xD;
          -  Patients with an active infection or with a fever &gt; 101.30 F within 3 days of the&#xD;
             first scheduled day of protocol treatment&#xD;
&#xD;
          -  History of prior malignancy within the past 3 years except for curatively treated&#xD;
             basal cell carcinoma of the skin, cervical intra-epithelial neoplasia, or localized&#xD;
             prostate cancer with a current PSA of &lt; 1.0 mg/dL on 2 successive evaluations, at&#xD;
             least 3 months apart, with the most recent evaluation no more than 4 weeks prior to&#xD;
             entry&#xD;
&#xD;
          -  Patients with known hypersensitivity to any of the components of Oxaliplatin and&#xD;
             Pemetrexed&#xD;
&#xD;
          -  Patients who received any chemotherapy, radiation therapy or surgical resection other&#xD;
             than diagnostic biopsies for HNSCC prior to the first scheduled day of protocol&#xD;
             treatment&#xD;
&#xD;
          -  Patients who are receiving concurrent investigational therapy or who have received&#xD;
             investigational therapy within 30 days of the first scheduled day of protocol&#xD;
             treatment(investigational therapy is defined as treatment for which there is currently&#xD;
             no regulatory authority approved indication)&#xD;
&#xD;
          -  Peripheral neuropathy ≥ Grade 2&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
&#xD;
          -  Any other medical condition, including mental illness or substance abuse, deemed by&#xD;
             the Investigator to be likely to interfere with a patient's ability to sign informed&#xD;
             consent,cooperate and participate in the study, or interferes with the interpretation&#xD;
             of the results.&#xD;
&#xD;
          -  History of allogeneic transplant&#xD;
&#xD;
          -  Known HIV (active, previously treated or both)&#xD;
&#xD;
          -  Presence of clinically detectable (by physical exam) third-space fluid collections,&#xD;
             for example, ascites or pleural effusions that cannot be controlled by drainage or&#xD;
             other procedures prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mitchell Memorial Cancer Center at Owensboro Medical Health System</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Purchase Cancer Group - Paducah</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Cancer Center at Jackson-Madison County General Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center - Cool Springs</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center at Franklin</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Meharry Medical College - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <results_first_submitted>February 7, 2012</results_first_submitted>
  <results_first_submitted_qc>February 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2012</results_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Jill Gilbert, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine; Director, Hematology/Oncology Fellowship Program; Section Chief, Solid Tumor Oncology; Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was open to accrual from 12/13/2006 to 4/9/2008.</recruitment_details>
      <pre_assignment_details>This study consented 42 patients. One patient was found ineligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pemetrexed/Oxaliplatin</title>
          <description>Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pemetrexed/Oxaliplatin</title>
          <description>Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Response to Treatment Measured by RECIST Criteria</title>
        <description>RECIST response categories: Progressive disease (PD): &gt;=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): &gt;=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.</description>
        <time_frame>at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pemetrexed/Oxaliplatin</title>
            <description>Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Response to Treatment Measured by RECIST Criteria</title>
          <description>RECIST response categories: Progressive disease (PD): &gt;=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): &gt;=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pemetrexed/Oxaliplatin</title>
          <description>Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>myelosupression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>hearing loss, sudden</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Esophagus pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>obstructed PEG tube</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection, port-a-cath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ANC/AGC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>tracheostomy tube changed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT/PE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The two cohorts of pemetrexed and oxaliplatin patients represented similar populations, thus the response data were combined.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jill Gilbert, M.D.</name_or_title>
      <organization>Vanderbilt-Ingram Cancer Center</organization>
      <phone>615-343-4677</phone>
      <email>jill.gilbert@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

